Abstract
IntroductionAfatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a Named Patient Use (NPU) programme. Patients and methodsRetrospective data for 63 patients were collected, including demographics, dose, toxicity and clinical efficacy. ResultsResponse rate and median PFS were 14.3% and 2.6months, respectively. Diarrhoea and rash were the most common toxicities; 46% of patients required a dose reduction and 41% had a dose delay. ConclusionsEfficacy and safety in the NPU programme are consistent with the LUX-Lung 1 trial.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
